Indian Journal of Respiratory Care

IJRC Email      Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  13 (2024)
Volume  12 (2023)
Volume  11 (2022)
Volume  10 (2021)
Volume  9 (2020)
Volume  8 (2019)
Volume  7 (2018)
Volume  6 (2017)
Volume  5 (2016)
Volume  4 (2015)
Volume  3 (2014)
Volume  2 (2013)
Volume  1 (2012)
Related articles

VOLUME 9 , ISSUE 2 ( July-December, 2020 ) > List of Articles

REVIEW ARTICLE

Management of Chronic Obstructive Pulmonary Disease: Insights into Patient Profile – Use of Inhaled Corticosteroids/Long-Acting β2-Agonists or Long-Acting β2-Agonists/Long-acting Muscarinic Antagonists

Nevin Kishore, Mrinal Sircar

Keywords : Bronchodilators, chronic obstructive lung disease, eosinophil count, exacerbations, inhaled corticosteroids, long-acting muscarinic antagonists, long-acting β2-agonists, smoking

Citation Information : Kishore N, Sircar M. Management of Chronic Obstructive Pulmonary Disease: Insights into Patient Profile – Use of Inhaled Corticosteroids/Long-Acting β2-Agonists or Long-Acting β2-Agonists/Long-acting Muscarinic Antagonists. Indian J Respir Care 2020; 9 (2):162-170.

DOI: 10.4103/ijrc.ijrc_56_19

License: CC BY-NC-SA 4.0

Published Online: 08-12-2022

Copyright Statement:  Copyright © 2020; Indian Journal of Respiratory Care.


Abstract

The noncommunicable chronic obstructive pulmonary disease (COPD) ranks among the top five leading causes of death worldwide. It is a preventable chronic disease that has become a major public health concern globally, as well as in India. To improve the pharmacotherapeutic management of COPD and to increase awareness about the prevalence of the disease, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has updated recommendations for the disease, based on the current clinical evidence. The present GOLD guideline endorses inhaled corticosteroids (ICS) combined with long-acting β2-agonists (LABA) for a subgroup of patients. The article is an attempt to clearly define patient profiles that stand to benefit from ICS/LABA, LABA/long-acting muscarinic antagonists (LAMA), and ICS/LABA/LAMA combination therapy based on current clinical evidence. The discussion is presented under the following headings: (i) disease burden worldwide, as well as in India; (ii) clinical symptoms and diagnosis of disease; (iii) risk factors leading to the development of disease; (iv) pharmacotherapeutic agents for COPD; (v) current updated recommendations from GOLD guidelines; (vi) subgroup of patients who can benefit from various combinations of therapeutic agents; and (vii) comparative analysis of clinical studies on various GOLD guideline-suggested combination therapies.

HTML PDF Share
  1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD; 2018. Available from: http://www.goldcopd.org/. [Last accessed on 2018 Mar 19].
  2. Tuder RM, Petrache I. Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest 2012;122:2749-55.
  3. Rabe K, Henrik W. Chronic obstructive pulmonary disease. Lancet 2017;389:1931-40.
  4. Vijayan VK. Chronic obstructive pulmonary disease. Indian J Med Res 2013;137:251-69.
  5. Koul PA. Chronic obstructive pulmonary disease: Indian guidelines and the road ahead. Lung India 2013;30:175-7.
  6. Jindal SK. COPD: The unrecognized epidemic in India. J Assoc Physicians India 2012;60 Suppl: 14-6.
  7. Bhome AB. COPD in India: Iceberg or volcano? J Thorac Dis 2012;4:298-309.
  8. Anzueto A, Ferguson GT, Feldman G, Chinsky K, Seibert A, Emmett A, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 2009;6:320-9.
  9. Antus B. Pharmacotherapy of chronic obstructive pulmonary disease: A clinical review. ISRN Pulmonol 2013;2013:Article ID 582807, p 1-11.
  10. Ejiofor S, Alice M. Pharmacotherapies for COPD. Clin Med Insights Circ Respir Pulm Med 2013;7:17-34.
  11. Lipworth B, Jabbal S. A pragmatic approach to simplify inhaler therapy for COPD. Lancet Respir Med 2017;5:679-81.
  12. Roversi S, Lorenzo C, Enrico C. GOLD 2017 recommendations for COPD patients: Toward a more personalized approach. COPD Res Practice 2017;3:5.
  13. Cazzola M, Rogliani P, Puxeddu E, Ora J, Matera MG. An overview of the current management of chronic obstructive pulmonary disease: Can we go beyond the GOLD recommendations? Expert Rev Respir Med 2018;12:43-54.
  14. Ferreira AJ, Reis A, Marçal N, Pinto P, Bárbara C; GI DPOC-Grupo de Interesse na Doença Pulmonar Obstrutiva Crónica. COPD: A stepwise or a hit hard approach? Rev Port Pneumol (2006) 2016;22:214-21.
  15. Cazzola M, Calzetta L, Rogliani P, Matera MG. The challenges of precision medicine in COPD. Mol Diagn Ther 2017;21:345-55.
  16. Segreti A, Stirpe E, Rogliani P, Cazzola M. De?ning phenotypes in COPD: An aid to personalized healthcare. Mol Diagn Ther 2014;18:381-8.
  17. Vogelmeier C. Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364:1093-103.
  18. Zhoung N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, et al. LANTERN: A randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis 2015;10:1015-26.
  19. Horita N, Goto A, Shibata Y, Ota E, Nakashima K, Nagai K, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev 2017;2:CD012066.
  20. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. BMJ 2000;320:1297-303.
  21. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-9.
  22. Larsson K, Janson C, Lisspers K, Jørgensen L, Stratelis G, Telg G, et al. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: The PATHOS study. J Intern Med 2013;273:584-94.
  23. Perrone V, Sangiorgi D, Buda S, Degli Esposti L. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: Findings from a real-world analysis in an Italian setting. Int J Chron Obstruct Pulmon Dis 2016;11:2749-55.
  24. Blais L, Forget A, Ramachandran S. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. Clin Ther 2010;32:1320-8.
  25. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
  26. Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): A double-blind randomised controlled trial. Lancet 2016;387:1817-26.
  27. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta (2)-agonist in one inhaler versus long-acting beta (2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;4:CD006829.
  28. Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: A post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016;4:390-8.
  29. Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: Two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013;1:210-23.
  30. Crim C, Mark TD, Jean B, Paul WJ, Nicola AH, Donald A. et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc 2015;12:27-34.
  31. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thora×2013;68:1029-36.
  32. Janson C, Larsson K, Lisspers KH, Ställberg B, Stratelis G, Goike H, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2agonist: Observational matched cohort study (PATHOS). BMJ 2013;346:3306.
  33. Kern DM, Davis J, Williams SA, Tunceli O, Wu B, Hollis S, et al. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: A US administrative claims database study. Respir Res 2015;16:52.
  34. Halpin DM, Gray J, Edwards SJ, Morais J, Singh D. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: A systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. Int J Clin Pract 2011;65:764-74.
  35. Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): A double-blind, parallel group, randomised controlled trial. Lancet 2017;389:1919-29.
  36. Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, et al. FULFIL Trial: Once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017;196:438-46.
  37. Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:741-50.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.